HORIZON-HLTH-2027-02-TOOL-01-two-stage

AI-enabled predictive biomarkers for chronic diseases

Horizon EuropeCluster 1 · HealthResearch and Innovation Action (RIA) · two-stage

Predictive biomarkers of disease progression and treatment response using AI and multimodal evidence for chronic non-communicable diseases. This briefing highlights the opportunity at a practical level; the official topic conditions remain binding.

HORIZON-HLTH-2027-02-TOOL-01-two-stage

AI-enabled predictive biomarkers for chronic diseases

Predictive biomarkers of disease progression and treatment response using AI and multimodal evidence for chronic non-communicable diseases.

Type of actionResearch and Innovation Action (RIA) · two-stageOpening10 February 2027Deadline13 April 2027 · Stage 1ProgrammeCluster 1 · Health

Core intervention logic

  1. 1Select the clinical questionDevelop predictive biomarker signatures using AI methodologies
  2. 2Integrate multimodal dataIntegrate multimodal clinical, molecular and digital data
  3. 3Train and validate modelsValidate clinical utility for progression or treatment response
  4. 4Demonstrate clinical utilityDevelop predictive biomarker signatures using AI methodologies

How the action works

Starting point
Select the clinical question
↓
Integrate multimodal data↔Train and validate models
↓
Demonstrate clinical utility

Earlier and more personalised decisions for chronic disease management.

Expected impactEarlier and more personalised decisions for chronic disease management.Stronger European collaborationEvidence that supports uptakeValue beyond the grant
Key message:Predictive biomarkers of disease progression and treatment response using AI and multimodal evidence for chronic non-communicable diseases.EXELIXIS Research Management & Communication
A practical visual reading of the call’s intervention logic, consortium needs, expected outputs and route to impact.

Who is it for?

Clinical cohorts and disease-domain researchers; AI, biomarker, omics and digital-health teams; Hospitals, patients, SMEs and regulatory specialists. The strongest consortia will connect these capabilities around a clearly defined need rather than assemble partners only to satisfy formal eligibility.

What does the call support?

Develop predictive biomarker signatures using AI methodologies.

Integrate multimodal clinical, molecular and digital data.

Validate clinical utility for progression or treatment response.

What are the key requirements?

Proposal perspective

A competitive proposal must connect the topic’s expected outcomes to a focused intervention logic, credible partners, measurable results and a convincing route to uptake. Scope, eligibility and all special conditions should be checked against the official topic text before consortium commitments are made.

Timeline and next steps

The topic is scheduled to open on 10 February 2027 and the deadline is 13 April 2027 · Stage 1. Prospective applicants should use the preparation period to confirm fit, shape the core concept, identify the capabilities required and build the work plan around the expected outcomes.

EXELIXIS can support call interpretation, concept positioning, consortium architecture, proposal development, impact pathways and coordination of partner contributions.

Discuss this opportunity with EXELIXIS →

Official sources

This briefing is an original summary prepared from official EU sources. It is provided for orientation and does not replace the binding call text, General Annexes or Funding & Tenders Portal conditions.